It's Time for a Simplified Approach to Hepatitis B Elimination

Douglas Dieterich, MD, Camilla Graham, MD, MPH, Su Wang, MD, MPH, Paul Kwo, MD, Young-Suk Lim, MD, PhD, Chun-Jen Liu, MD, PhD, Kosh Agarwal, MD, Mark Sulkowski, MD

PII: S2772-5723(22)00170-4
DOI: https://doi.org/10.1016/j.gastha.2022.10.004
Reference: GASTHA 199

To appear in: Gastro Hep Advances

Received Date: 3 March 2022
Revised Date: 30 September 2022
Accepted Date: 4 October 2022


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier, Inc on behalf of the AGA Institute
It’s Time for a Simplified Approach to Hepatitis B Elimination

**Corresponding Author:** Douglas Dieterich, MD: Department of Medicine, Division of Liver Disease, Icahn School of Medicine at Mount Sinai, NY, United States of America. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. Douglas.dieterich@mountsinai.org

Camilla Graham, MD, MPH: Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. cgraham@bidmc.harvard.edu

Su Wang, MD, MPH: Center for Asian Health, Saint Barnabas Medical Center, RWJ Barnabas Health, Florham Park, NJ, United States of America. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. Suwang8@gmail.com

Paul Kwo, MD: Department of Gastroenterology and Hepatology, Stanford Medical Center, Pleasanton, CA, United States of America. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. pkwo@stanford.edu

Young-Suk Lim, MD, PhD: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. limys@amc.seoul.kr

Chun-Jen Liu, MD, PhD: Department of Internal Medicine and Hepatitis Research Center at the National Taiwan University Hospital, Taipei, Taiwan. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. cjiu@ntu.edu.tw

Kosh Agarwal, MD: Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London, England. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. Kosh.agarwal@kcl.ac.uk

Mark Sulkowski, MD: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America. Attended virtual consensus meeting, developed manuscript content and treatment algorithm, and reviewed final manuscript for submission. msulkowski@jhmi.edu

[Data, analytic methods, and study materials will not be made available to other researchers due to the nature of this paper.]

**Potential Competing Interests**
DD has served in a consulting capacity for Intercept Pharmaceuticals and Gilead. CG does not have any potential conflicts of interest. SW has served in an advisory/consulting capacity for Gilead and
has received research grants from Gilead Sciences. PK has served in a consulting/advisory capacity to Gilead, Aligos, Abbvie, Mallinckrodt, TwoXR, SUrrozen, HepQuant, Syneos, Durect, and Ambys; he has received institutional grants from Gilead, BMS, Assembly Biosciences and DSMB Janssen. YL has received grants, non-financial support, and other support from Gilead Sciences, apart from the submitted work. KA has served in an advisory/consulting capacity for Aligos, Assembly, Arbutus, Boehringer Ingelheim, Springbank, Roche, Janssen, Immunocore, Gilead, Sobi, Shinoigi, and Sandoz; he has served as a speaker for Gilead and Sobi. CL has served in an advisory capacity for Gilead and has received grants from MSD. MS has served in a consulting/advisory capacity to Antios, Arbutus, Assembly Biosciences, AbbVie, Gilead, Virion, and Viv and has received research grants from AbbVie, Gilead Sciences, Assembly Biosciences, and Janssen Pharmaceuticals. In addition, MS sat on a Data Monitoring Committee for Gilead and AbbVie, as well as an outcome adjudication committee for FH360.

Financial Support
The meeting and manuscript were funded by Gilead Sciences. Project management and logistical support for the meeting was provided by The Kinetix Group and funded by Gilead Sciences. Writing support was provided by Jamie Kelly, Pharm D of JK Clinical Solutions, LLC and was funded by The Kinetix Group. Gilead Science’s role was limited to non-participative attendance of the consensus meeting. Gilead Sciences did not review content of manuscript. Opinions expressed in the manuscript are solely indicative of the providers involved in the consensus meeting.

Ethical Statement
The corresponding author, on behalf of all authors, jointly and severally, certifies that their institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.
Acknowledgements

Jamie Kelly, Pharm. D of JK Clinical Solutions provided medical writing support for the manuscript.

Word count: 6,283
Abstract

Background and Aims

Hepatitis B virus (HBV) infection continues to threaten millions of lives across the globe, despite universal vaccination efforts. Current guidelines for screening, vaccination, and treatment are complex and have left too many people undiagnosed or improperly managed. Antiviral therapy has been shown to significantly reduce the incidence of liver-related complications, including liver cancer. However, the complexity of existing guidelines can make it difficult to identify which patients to target for treatment, and recommendations that are difficult to implement in real-world settings pose a barrier to eligible patients to receive therapy and contribute to health disparities in HBV care. The goal of this global expert panel was to gain consensus on a streamlined approach to HBV care to facilitate implementation of HBV intervention and treatment, especially in the primary care setting.

Methods

A group of eight liver and infectious disease specialists attended a meeting in January 2021 with the objective of gaining consensus on a streamlined algorithm for HBV care that would encourage implementation of HBV intervention and treatment.

Results

We have created a comprehensive perspective highlighting screening optimization, diagnostic workup, treatment, and monitoring. This treatment algorithm is designed to provide a streamlined visual pathway for risk stratification and management of patients with HBV that can be adapted in various care settings.

Conclusion

Simplification of guidelines will be critical to achieving health equity to address this public health threat and achieve HBV elimination.
Key words: Hepatitis B, simplified treatment, HBV algorithm

Introduction

Hepatitis B (HBV) infection is the leading cause of hepatocellular carcinoma (HCC) and liver-related deaths worldwide, causing 780,000 HBV-related deaths each year. More than 2 billion people have been infected with HBV worldwide, of which 296 million people were living with chronic HBV infection in 2019; by comparison, 58 million people were living with hepatitis C (HCV) infection in 2019 and 38 million were living with human immunodeficiency virus (HIV) in 2019. HBV is an ongoing viral pandemic with an estimated 1.5 million new HBV infections each year despite the existence of highly effective vaccines.

The WHO aims to achieve elimination of HBV as a public health threat and has set goals to increase the diagnosis of people infected to 90% and to reduce the number of people dying from HBV infection by 65% by 2030. Yet not a single country is on track to achieve the WHO HBV mortality goal by 2030. Decentralized care and primary care health providers are the key to the expansion of testing, vaccination, and treatment in order to reach hepatitis elimination global targets. Shifts of decentralizing have already begun with hepatitis C globally and have led to increases in screening and linkage to care and treatment. Such task shifting towards primary care and frontline workers is also much needed for HBV, or its elimination as a public health threat will not be achieved.

The current HBV guidelines and recommendations are directed towards specialists (whether gastroenterologists, hepatologists, or infectious disease specialists), and data shows that significant gaps in care persist. Many people living with HBV are not receiving regular monitoring for their HBV treatment or liver cancer screening. Key challenges include complex and difficult to implement, risk-based recommendations for screening and vaccination. Current treatment guidelines leave many patients uncategorized, who often require experience and judgement for management.
Recommendations that are difficult to implement or ambiguous recommendations are barriers for treatment. These challenges lead to the exacerbation and perpetuation of health care disparities in populations who often already experience societal inequalities. The simplification of guidelines is critical to health equity, and a few working groups have simplified algorithms for primary care providers.\textsuperscript{12,13} However, our expert panel recognizes the need for further simplification and set forth to gain consensus on a streamlined approach for HBV care encompassing screening, vaccination, diagnostic workup, treatment, monitoring, and particularly, driving patient awareness.

**Screening for HBV: An Integral Part of Liver Cancer Prevention**

Screening is a crucial tool in the global elimination of HBV. The asymptomatic nature of HBV disease drives the need to implement a proactive screening approach with the goal of identifying those who require vaccination, disease progression monitoring, and HCC surveillance, and of treating those at risk for complications.\textsuperscript{14–16} Most guidelines recommend general population screening in countries with intermediate to high seroprevalence (\(\geq 2\%\)) and risk-based screening for all other countries.\textsuperscript{14–19} However, this screening approach has failed to achieve significant progress in increasing the diagnosis of HBV. Only 10\% of those with chronic HBV across the globe were diagnosed in 2019, a minor progress towards achieving the 2030 WHO goals.\textsuperscript{4,20,21}

Several studies have demonstrated that fewer than half of primary care providers are screening at-risk patients.\textsuperscript{22–25} Risk-based screening failed to identify sufficient numbers of patients with HCV or HIV infection, and thus the guidelines for these infections have shifted to a universal, one-time test for all adults. A recent cost-effectiveness study demonstrated that universal HBV and related screenings of adults in the US could save an additional $263,000 for every 100,000 adults screened as compared with current screening practices.\textsuperscript{26} Two additional cost-effectiveness studies
have demonstrated that general population screening of HBV in adults remained economically feasible even in populations with low seroprevalence (as low as 0.3–1.5%).

Our expert panel recommends universal, one-time testing for HBV for all adults and for all pregnant women with each pregnancy (see Figure 1.) All adults over age 18 should be screened at least once in their lifetime, which will also ensure that those who did not mount an antibody response with infant vaccination or who were never vaccinated are identified and vaccinated.

Trio of HBV Serologic Markers

The following tests are recommended when screening for HBV infection:

- **HBV surface antigen (HBsAg)**, if reactive or positive, indicates the presence (acute or chronic) of HBV infection (detectable as early as 1 to 2 weeks after infection)
- **Antibodies to HBsAg (anti-HBs)**, if reactive or positive, indicates immunity against HBV either from vaccination or seroconversion from prior HBV infection
- **Antibody to the core antigen of HBV (total anti-HBc)**, if reactive or positive, indicates exposure to HBV with previous or current infection (detectable around 3 months after infection)

The panel recommends universal vaccination against HBV in all patients who have negative serologies, given that it is impossible to determine potential future risks for exposure to HBV.

Recently, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended HBV vaccination for all adults aged 19 through 59 years and those age 60 or older with risk factors. Given the high rate of risk factors, such as diabetes and fatty liver disease in older patients, universal vaccination will be a more simplified approach for implementation. We strongly recommend testing adults prior to vaccination to avoid the risk of false reassurance for patients who already have chronic HBV infection. In patients with previously known anti-HBs reactivity, but current negative anti-HBs test results, re-vaccination (a single booster) is only recommended for health care workers (HCWs), sexual partners of persons with HBV, people who use drugs, chronic hemodialysis patients, and
immunocompromised people (e.g., those with HIV). Point-of-care hepatitis B testing is available and could be a valuable option in expanding accessibility, especially in low-resource settings, and help reduce costs of widespread testing.\textsuperscript{31}

**Reactive antibody to the core antigen of HBV (total anti-HBc):**

Patients with reactive anti-HBc antibody have most likely been exposed to HBV and have HBV genetic material within their hepatocytes. When these patients receive immunosuppressive medications, such as certain cancer chemotherapies, high dose steroids, or biologics for autoimmune diseases, they are at risk for reactivation of HBV and can develop serious complications, such as liver failure.\textsuperscript{32,33}

Recommendations for the management of these patients is beyond the scope of this perspective, but they may benefit from expert consultation, especially if they will potentially receive chemotherapy or biologic agents. If there is any concern that a repeated, isolated anti-HBc Ab could be a false positive result, it is not harmful to provide HBV vaccination, but these patients should still be considered at risk for reactivation.\textsuperscript{34}

**Screening recommendations**
- Perform one-time testing of HBV in all adults who were not vaccinated at birth (born before 1991 for the U.S.), with each pregnancy, and in those at high risk for HBV infection regardless of age
- Use HBsAg, anti-HBs, and total anti-HBc as serologic markers for screening
- Patients with negative serological markers should be vaccinated
- Patients with anti-HBc positive results should be counseled about the risk of reactivation with immunosuppressive conditions
- Patients with HBsAg should undergo evaluation for treatment

**Education for patients with chronic HBV infection**
- Inform about HBV tests and how to interpret the results
- Reassure patients that they can live a long and healthy life with ongoing care
- Review ways to minimize risk of transmission and need for further workup to determine if treatment is necessary
- Counsel on protecting the liver through limiting alcohol, avoiding herbals and supplements, and the need for screening/vaccination for hepatitis A
- Connect patients with substance use with harm-reduction services
**Diagnostic Workup to Determine Treatment Eligibility**

Patients who are found to be HBsAg positive require additional evaluation, education, counseling, and consideration of antiviral therapy (Table 1 and Figure 1). Patients should undergo a physical examination, blood work, and cirrhosis screening to identify whether or not they would benefit from antiviral treatment (Table 2).

A physical examination should be performed to look for stigmata of cirrhosis (e.g., jaundice, hepatomegaly, splenomegaly, palmar erythema, ascites, spider hemangiomas, gynecomastia, encephalopathy) and extra-hepatic manifestations (e.g., vasculitis, glomerulonephritis, fever). Factors that may influence liver health, such as obesity, alcohol consumption, and other comorbid conditions (e.g., diabetes, metabolic syndrome, and renal disease) should also be taken into consideration and addressed as part of lifestyle health and well-being maintenance. Laboratory testing should include tests that measure liver function and/or injury, HBV replication and infectivity (i.e., quantitative HBV DNA), and the presence and prevention of comorbidities (Table 2). In a setting in which HBV DNA testing is not routinely accessible, the WHO guidelines provide guidance for antiviral therapy based on consideration of the patient’s age and serum ALT level.\(^\text{15}\)

**Cirrhosis Screening**

Cirrhosis screening is an important step in determining the appropriate HBV management pathway. Liver biopsy remains the gold standard for the assessment of fibrosis stage as well as the diagnosis of liver cirrhosis. However, the panel recommends that all patients undergo liver disease assessment based on readily accessible laboratory tests, such as AST, ALT, and platelet count. Specifically, clinicians should calculate the aspartate aminotransferase (AST)-to-platelet ratio index
(APRI; https://www.hepatitisc.uw.edu/page/clinical-calculators/apri) and/or the Fibrosis-4 (FIB-4; https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4). For both tests, a higher score indicates a higher likelihood of advanced liver fibrosis. In addition, all patients should also undergo a baseline ultrasound of the liver with alpha-fetoprotein (AFP) to assess for the presence of HCC. While ultrasound of the liver has relatively moderate sensitivity for detecting HCC at an early stage, obtaining an AFP may improve sensitivity of early HCC detection.¹

Alternatively, other non-invasive modalities, such as vibration controlled elastography, magnetic resonance elastography and enhanced liver fibrosis testing can be considered, however, these may be costly or not available in most primary care centers.

**Diagnostic workup recommendations**
- Perform physical exam for stigmata of cirrhosis and extrahepatic manifestations
- Obtain HBV DNA level, liver tests (i.e., CBC, AST, ALT, and co-infection status)
- Calculate APRI or FIB-4 to detect advanced fibrosis or cirrhosis
- Screen for HIV, HDV, and HCV coinfections
- Screen for HCC by ultrasound and AFP

**Education for patients with HBV**
- Reiterate ways to minimize risk of transmission
- Discuss risks of cirrhosis and HCC as related to HBV
- Provide patient education materials and support

**Treatment for an Oncogenic Virus**

HBV infection is considered oncogenic due to direct and indirect mechanisms that cause an increase in the risk of HCC.³⁵ Persons with chronic HBV infection (HBsAg positive) are at a 25- to 37-fold increased risk of HCC compared to non-infected people. The approach to treating HBV should be focused on reducing the carcinogenicity of hepatitis B virus infection through antiviral treatment.

Currently there is no cure for HBV, but goals of antiviral therapy are to suppress viral replication and
to reduce the risk of mortality, HCC, progression of liver disease, and transmission to others, particularly mother-to-child transmission in pregnancy.\textsuperscript{12,14–18,29,36} Despite the strong association of chronic HBV infection with HCC, many patients at risk for HCC go untreated for HBV infection.\textsuperscript{8,37} In 2016, only 1.7\% of all persons with chronic HBV received treatment worldwide.\textsuperscript{37} Data collected from CDC’s US Chronic Hepatitis Cohort Study (CHeCS) show unacceptably low treatment of HBV patients with cirrhosis (only 56\% with cirrhosis were on HBV antiviral therapy).\textsuperscript{38} A follow-up of this study showed that treating HBV was associated with a 61\% lower HCC risk.\textsuperscript{39}

\textit{Treatment Eligibility}

The panel recognized that existing guidelines are confusing, ambiguous, and leave many patients with HBV infection in a “grey” area where there is no clear guidance on how to manage them. The panel reviewed how these patients are actually being treated in their respective practices and reviewed the literature on clinical outcomes for patients who do not fit into treatment categories specified in other guidelines. The goal was to have clear management strategies for all patients with HBV infection. The shared approach was to assume that all patients with chronic HBV infection need to be treated, and then to exclude those who do not “qualify” for treatment, rather than the currently prevailing, reverse perspective, to reduce the number of patients who are not receiving appropriate treatment. Therefore, we recommend utilizing three objective factors: severity of liver disease, age, and HBV DNA level. With this approach, hepatitis B e antigen (HBeAg) or hepatitis B e antibody (anti-HBe) is not required in treatment decision making, as it does not add further discriminating information, but instead may contribute to confusion around selecting appropriate treatment candidates.

All persons who have stigmata of cirrhosis and/or a fibrosis assessment that suggests cirrhosis (i.e., APRI score \textgreater 2.0; FIB-4 \textgreater 3.25) with any detectable HBV DNA should initiate antiviral treatment
with oral nucleos(t)ide analogues, regardless of age or HBV DNA level. Patients with cirrhosis, compensated or decompensated, or with a mass on ultrasound or other liver imaging, should be referred immediately to a specialist, regardless of HBV DNA level, due to additional complex management of cirrhosis and cancer (see Figure 1 for other instances needing consultation). In addition, patients with HIV, HCV, and/or delta virus (HDV) coinfection should also be referred to an HBV specialist.

When cirrhosis is not present, we recommend using the patient’s age and HBV DNA level to determine treatment necessity and monitoring decisions. There is clinical evidence demonstrating that HBV DNA levels of >2,000 IU/mL are associated with an increased risk of HCC or progression to cirrhosis, regardless of HBeAg status or ALT level. Based on recent clinical data and real-world experience, the expert panel recommends antiviral treatment of all patients > 30 years of age with HBV DNA levels > 2,000 IU/mL, regardless of ALT level or HBeAg status, and of all patients < 30 years of age with HBV DNA levels > 2,000 IU/mL along with ALT above the upper limit of normal on repeat testing (Figure 1). Similarly, the WHO guidelines utilize the > 30 years of age, when no cirrhosis is present, as a threshold for treatment.

With expanding treatment to more patients, concern arises for the cost-effectiveness of such interventions. The cost of generic HBV treatments is relatively low. Several studies have demonstrated that treating all patients diagnosed with chronic HBV is cost-effective. Lepers and colleagues analyzed different treatment models to determine the most cost-effective strategy in France and found that broadening treatment eligibility to include the treatment of all patients soon after being diagnosed with chronic HBV infection was the most cost-effective strategy. Lim and colleagues demonstrated that using HBV DNA level of >2,000 IU/mL alone for non-cirrhotic patients and removing ALT and HBeAg treatment eligibility parameters would avoid 43,300 cases of HCC, save 37,000 lives in Korea, and be considered highly cost-effective.
Treatment Options

Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide fumarate (TAF) are second generation nucleos(t)ide analogues (NAs) that inhibit HBV DNA replication and are recommended as first-line, monotherapy agents due to their lower risk of drug resistance, as compared to other NAs.¹⁵,¹⁶,²⁹ The surrogate marker of treatment response is sustained HBV DNA suppression at undetectable levels, while the primary endpoint at which therapy could potentially be discontinued is HBsAg loss.¹⁶,²⁹ While HBsAg loss is not considered a “virological” or “sterilizing” cure, since covalently closed circular DNA (cccDNA) typically persists within the hepatocytes of persons with resolved HBV infection, this is recognized as a “functional” cure. Interferon (IFN) therapy is not recommended as a first-line therapy due to the low rate of serological responses, delivery mode (i.e., injection), poor tolerability, and the need for close monitoring, despite being a finite treatment with statistically greater potential for HBsAg loss, as compared to NAs.¹⁵,⁵² The WHO recommends switching to TDF or TAF in patients with suspected antiviral resistance to lamivudine, ETV, adefovir, or telbivudine (defined as failure of drug to reduce HBV DNA levels by ≥ 1 x log₁₀ IU/mL within 3 months of initiating treatment or rebound of ≥ 1 x log₁₀ IU/mL in patients with initial response).¹⁵ Lack of response or rebound of HBV DNA level in patients with initial response warrants referral to an HBV specialist.

Table 3 provides information on the dosing and key considerations of ETV, TDF, and TAF. TAF is not recommended in patients with decompensated cirrhosis (Child-Turcotte-Pugh CTP [CTP] B or C), although recent data presented at the European Association for the Study of the Liver (EASL) 2020 conference demonstrated high rates of viral suppression and stable safety outcomes in chronic HBV patients with hepatic impairment (CTP ≥ 7 and ≤ 12) who switched from TDF to TAF.⁵³,⁵⁴ Resistance to ETV has been reported in patients with pre-exposure to lamivudine, especially in those who were
treatment resistant; as such, ETV is not recommended for persons with prior exposure to lamivudine, and TDF or TAF is recommended for these patients.\textsuperscript{55-58} All first-line treatments are generally well tolerated, including among patients with cirrhosis.\textsuperscript{14,16}

**Treatment recommendations**
- Treat all patients with cirrhosis (with detectable HBV DNA)
- Treat all patients > 30 years of age and HBV DNA > 2,000 IU/mL if they have no evidence of cirrhosis
- Refer to specialist if decompensated cirrhosis is suspected or if HIV coinfection exists
- Use ETV, TDF, or TAF as first-line agents for treatment of HBV

**Education for patients with HBV**
- Address access to therapy in addition to cost
- All appropriate family members should be screened for HBV
- Be optimistic about future research and treatments for HBV
- Engage patients in treatment decision process to enhance adherence
- Discuss potential side effects, including bone mineral density and renal function with TDF therapy

**Optimizing Long-Term Outcomes with Monitoring**

In patients on antiviral therapy, ongoing monitoring is necessary to detect HCC and liver disease progression, as well as treatment response, toxicity, and adherence. HBV DNA suppression, the strongest predictor of disease progression and long-term outcomes, is achieved by 24 to 48 weeks of treatment with TDF, TAF, or ETV in at least half of patients with HBV monoinfection.\textsuperscript{15,29} It is also an excellent marker to use for adherence. In patients starting treatment, we recommend scheduling an in-person office visit, or a telemedicine telephone or video consultation, around three months after starting therapy to check in with the patient regarding treatment adherence and any side effects, as well as to provide an opportunity for additional patient counseling. The results of a recent nationwide, population-based cohort study demonstrated a more than 30% reduction in risk of death and/or transplantation in patients who were fully adherent (≥ 90%), which was more than 60% of the patients in this study, compared with those with partial adherence (< 90%).\textsuperscript{59} While single, daily dosing of
antivirals coupled with minimal side effects can positively influence adherence, barriers similar to other long-term treatments for chronic diseases such as asymptomatic disease, forgetfulness, competing priorities, and patient-related factors continue to be an issue. Therefore, the importance of long-term treatment adherence should be regularly discussed with patients and novel approaches to improving adherence are still warranted.

Our expert panel recommends monitoring ALT and HBV DNA every 3 to 6 months until viral suppression is achieved, and then every 6 months; HBsAg testing should be conducted annually (see Figure 1). Genotypic resistance is low with first line ETV, TDF, and TAF and, therefore, testing is not recommended unless patients fail to respond to treatment or resistance is suspected. In low-resource settings, however, ALT can be performed every 6 months, and HBV DNA annually. In addition, cirrhosis screening should be conducted at least annually, and ultrasound with AFP for HCC surveillance should be performed every 6 months (see Figure 1). Renal function should be monitored at least annually in those patients receiving TDF therapy; monitoring may be increased for individuals with underlying kidney disease. Studies of up to 96 weeks have demonstrated TAF had significantly less progression of chronic kidney disease and bone mineral loss, as compared to TDF.\textsuperscript{60,61}

Newly diagnosed patients without cirrhosis who do not meet criteria for treatment initiation (see Figure 1) should have HBV DNA monitored every 6 months for approximately 2 years to ensure patients are truly in a low replicative state (HBV DNA levels consistently remain <2,000 IU/mL), and annually thereafter. Obtaining ultrasound with AFP is recommended every 6 months in patients ≥ 40 years of age. Patients born in Africa have a higher risk of early onset of HCC; therefore, we recommend HCC surveillance should begin at age 20 in these individuals.\textsuperscript{62} HBsAg and cirrhosis screening should be monitored every 2 years. In low-resource settings without access to HBV DNA
testing, ALT and ultrasound with AFP can be conducted once a year; if ALT rises above ULN, initiation of HBV treatment should be strongly considered.

**Stopping Treatment**

All patients with cirrhosis require lifelong treatment with NAs as severe liver injury can occur with HBV reactivation. In patients without cirrhosis, treatment should continue until therapeutic response has been achieved, defined as meeting all the following criteria: loss of HBsAg plus completing at least one additional year of treatment, maintaining persistently normal ALTs and undetectable HBV DNA, and willingness to undergo monitoring for HBsAg sero-reversion for at least 2 additional years. Only a small percentage of patients per year will achieve HBsAg loss; therefore, long-term, continuous treatment is required for most patients until novel drugs become available that can induce functional HBV cure.

**Monitoring recommendations**

- Obtain ALT and HBV DNA every 3 months for the first year, then every 6 months thereafter
- Perform ultrasound with AFP every 6 months
- Obtain HBsAg and assess fibrosis (testing consistent with cirrhosis) annually

**Education for patients with HBV**

- Connect patient to support services (e.g., patient assistance programs, copay cards, peer support)
- Discuss any side effects, challenges with adherence, etc.
- Promote maintenance of health and well-being; counsel patient on healthy lifestyle and assess for metabolic-associated fatty liver disease risk factors

**Conclusion**

Universal screening and the simplification of HBV care pathways for primary care providers and front-line workers are critical steps to finding the missing millions living with hepatitis B and to ensuring equitable access to life saving care for them. Adapting recommendations so they are realistic and implementable within diverse settings is important. We must also take into account resource limitations and the cost burden to patients in our complicated health care system and create
guidelines that are not so rigid as to become a barrier to care. Creating dashboards, registries, and electronic medical record tools are also valuable to support HBV monitoring. Educating patients and soliciting their treatment preferences are also part of ensuring that care has a meaningful impact on their lives. Increasing overall community awareness about hepatitis B, its link to liver cancer, and the interventions we have for testing, vaccination, and cure are importance messages, especially in affected communities. We must apply our scientific advances and medical recommendations with a lens of equity and population health if we are to achieve hepatitis B elimination.

Table 1. Interpretation of Serological Testing Results and Recommended Actions

<table>
<thead>
<tr>
<th>Test results</th>
<th>Action items</th>
<th>Patient education and counseling</th>
</tr>
</thead>
<tbody>
<tr>
<td>+ HBsAg</td>
<td>- HBsAg</td>
<td>+ Total anti-HBc</td>
</tr>
<tr>
<td>+ Anti-HBs</td>
<td>- Total anti-HBc</td>
<td>No further action required*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Anti-HBs</td>
<td>- Total anti-HBc</td>
<td>No further action required*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Anti-HBc, hepatitis B core antibody; Anti-HBs, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCW, health care worker; HIV, human immunodeficiency virus.

*Consult with a specialist if patient is on any immunosuppressive therapy.64
"Booster vaccine followed by serologic testing 1 to 2 months later is only recommended for HCWs, sexual partners or household contacts of persons with HBV, people who use drugs, persons with a history of incarceration, chronic hemodialysis patients, and immunocompromised people (e.g., those with HIV). If negative anti-HBs test, repeat the full vaccination series and retest 1 to 2 months after the last vaccine dose.13"

**Table 2. Simplified Approach for Hepatitis B Evaluation**

<table>
<thead>
<tr>
<th>Severity of liver disease</th>
<th>Level of viral replication</th>
<th>Presence and prevention of comorbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Stigmata of cirrhosis*</td>
<td>• HBV DNA quantitative</td>
<td>• Diabetes, metabolic syndrome, renal disease, other liver diseases</td>
</tr>
<tr>
<td>• Extrahepatic manifestations†</td>
<td></td>
<td>• Renal function</td>
</tr>
<tr>
<td>• CBC with platelets, INR</td>
<td></td>
<td>o Creatinine and eGFR</td>
</tr>
<tr>
<td>• Liver biochemistries</td>
<td></td>
<td>• Identify coinfections</td>
</tr>
<tr>
<td>o ALT, AST, ALP, total bilirubin, albumin, and creatinine</td>
<td></td>
<td>o Anti-HCV, anti-HIV, anti-HDV</td>
</tr>
<tr>
<td>• Calculate APRI and/or FIB-4</td>
<td></td>
<td>• Pregnancy test for all women of childbearing age</td>
</tr>
<tr>
<td>• Ultrasound of the liver with AFP</td>
<td></td>
<td>• Current medications</td>
</tr>
<tr>
<td>• Other noninvasive methods such as elastography, if available</td>
<td></td>
<td>(including as needed drugs, over the counter drugs, vitamins, herbs, and supplements)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Screen for STDs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Risk factors for progressive liver disease (i.e., alcohol consumption, obesity)</td>
</tr>
</tbody>
</table>

AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, aspartate aminotransferase [AST]-to-platelet ratio index; AST, aspartate aminotransferase; CBC, complete blood count; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; INR, international normalized ratio; FIB-4, Fibrosis 4; STD, sexually transmitted diseases.

*Stigmata of cirrhosis include jaundice, hepatomegaly, splenomegaly, palmar erythema, ascites, edema, spider hemangiomias, gynecomastia, asterixis, and encephalopathy.

†Extrahepatic manifestations include vasculitis, erythematous skin rash, fever, glomerulonephritis, polyarthritis, and cryoglobulinemia.65
Table 3. First-Line Treatments for Hepatitis B Infection

<table>
<thead>
<tr>
<th>Dosage and administration</th>
<th>Entecavir (ETV)</th>
<th>Tenofovir disoproxil fumarate (TDF)</th>
<th>Tenofovir alafenamide fumarate (TAF)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No cirrhosis or compensated cirrhosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dosage and administration</td>
<td>0.5 mg tablet once daily</td>
<td>300 mg QD</td>
<td>25 mg QD</td>
</tr>
<tr>
<td><strong>Decompensated cirrhosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dosage and administration</td>
<td>1 mg QD</td>
<td>300 mg QD</td>
<td>25 mg QD</td>
</tr>
<tr>
<td><strong>Prior treatment failure with lamivudine or telbivudine</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dosage and administration</td>
<td>Not recommended</td>
<td>300 mg QD</td>
<td>25 mg QD</td>
</tr>
<tr>
<td><strong>Use in renal impairment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dosage and administration</td>
<td>Dosage adjustment in eGFR &lt; 50 mL/min</td>
<td>Dosage adjustment in eGFR &lt; 50 mL/min</td>
<td>Not recommended in eGFR &lt; 15 mL/min not on hemodialysis</td>
</tr>
<tr>
<td><strong>Most common side effects</strong></td>
<td>Headache; fatigue; dizziness; and nausea*</td>
<td>Nausea†</td>
<td>Headache‡</td>
</tr>
<tr>
<td><strong>Key drug-drug interactions§</strong></td>
<td>Drugs that reduce renal function or compete for active tubular secretion</td>
<td>adefovir, didanosine, protease inhibitors, HCV antivirals</td>
<td>Drugs that strongly affect P-gp and BCRP activity, carbamazepine, phenytoin, rifampin, St. John’s wort</td>
</tr>
</tbody>
</table>

BCRP, breast cancer resistance protein; BMD, eGFR, estimated glomerular filtration rate; QD, every day; mg, milligram; mL, milliliter; min, minute; P-gp, P-glycoprotein.

*Most common adverse reactions of any severity in ≥3% of subjects with at least a possible relation to study drug.

†Most common adverse reactions in HBV-treated subjects with compensated liver disease.

‡Most common adverse reactions of any severity in ≥ 10% of subjects.

§Health care providers should consult prescribing information, their local pharmacist, and/or online tools (e.g., HEP Drug Interactions, http://www.hepdruginteractions.org) to confirm interaction or lack of interaction for specific drugs within a class, as exceptions may exist.
a. In particular, those who did not receive birth HBV vaccination (or unknown status) and all pregnant women with each pregnancy.

b. In settings in which HBV DNA testing is not routinely accessible, the WHO guidelines provide guidance for antiviral therapy based on consideration of the patient’s age and serum ALT level.\(^\text{10}\)

c. The upper limit of normal for ALT in healthy adults is 30 U/L for men and 19 U/L for females.\(^\text{11}\)

d. See Table 3 for more information about dosing and administration.

e. Patients often require long-term antiviral treatment; treatment can be stopped if patients meet all criteria: loss of HBsAg, complete ≥ 1 additional year of treatment, maintain persistently normal ALT and undetectable HBV DNA, and are willing to undergo monitoring for HBsAg sero-reversion for ≥ 2 additional years.

f. In low-resource settings, monitor ALT every 6 months and HBV DNA annually.

g. Use clinical judgement and shared decision making to determine if patient would benefit from or prefer treatment.

h. In low-resource settings, ALT and U/S with AFP can be conducted once a year; if ALT rises above upper limit of normal, initiation of HBV treatment should be strongly considered.

i. Age ≥ 20 in patients born in Africa.

j. Failure of drug to reduce HBV DNA levels by ≥ 1 x \(\log_{10}\) IU/mL within 3 months of initiating treatment or rebound of ≥ 1 x \(\log_{10}\) IU/mL in patients with initial response.

---


HBeAg positive chronic hepatitis B patients with high viral load and no significant ALT elevation. 


Vemlidy® (tenofovir alafenamide) tablets [prescribing information]. Foster City, CA: Gilead Sciences, Inc; March 2021.


Viread® (tenofovir disoproxil fumarate) tablets [prescribing information]. Foster City, CA: Gilead Sciences, Inc; April 2019.

### MONITOR

#### Antiviral therapy
- ALT + HBV DNA every 3–6 months until viral suppression achieved then every 6 months
- HBsAg every year
- Creatinine at least every year

#### Cirrhosis screening
- FIB-4, APRI, or FibroScan® every year

#### HCC surveillance
- U/S with AFP every 6 months

### SCREENING

**Universal, one-time HBV screening in all adults**
- (HBsAg, anti-HBs, and total anti-HBc)

**HBsAg positive**

**HBsAg negative**

### TREAT

**Age ≥ 30 AND HBV DNA >2,000**
- TREAT with ETV, TDF, or TAF

**Age <30 AND HBV DNA >2,000 AND ALT >ULN**
- TREAT with ETV, TDF, or TAF

**HBV DNA <2,000**
- DEFER

**Age <30 AND HBV DNA >2,000 AND ALT ≤ ULN**
- DEFER

### DIAGNOSTIC WORKUP

**At minimum (see Table 2 for full evaluation)**

- HBV DNA, ALT, AST, platelets
- Noninvasive tests such as FIB-4, APRI, or FibroScan®
- Baseline U/S of liver with AFP

### CONSULT WITH HBV SPECIALIST

- Cirrhosis and/or liver mass
- Platelets < 100 x 10^9/L
- HDV, HCV, and/or HIV coinfection
- Pregnancy
- Lack of response to treatment or rebound of HBV DNA levels

### SCREENING

**Universal, one-time HBV screening in all adults**
- (HBsAg, anti-HBs, and total anti-HBc)

**HBsAg positive**

**HBsAg negative**

### HCC surveillance

- U/S with AFP every 6 months

### HBsAg positive

#### HBV DNA <2,000
- DEFER

#### HBV DNA >2,000
- MONITOR
  - ALT + HBV DNA every 6 months for 2 years, then annually if no change
  - HBsAg every 2 years

### HBsAg negative

#### HBV DNA <2,000
- MONITOR
  - ALT + HBV DNA every 6 months for 2 years, then annually if no change
  - HBsAg every year

#### HBV DNA >2,000
- MONITOR
  - ALT + HBV DNA every 6 months for 2 years, then annually if no change
  - HBsAg every 2 years

### Cirrhosis screening

- FIB-4, APRI, or FibroScan® every year

#### HCC surveillance

- U/S with AFP every 6 months for age ≥ 40